NGM Biopharmaceuticals, Inc.
NGM
4
|
$12.92
-12.23%
0.0%
|
|
Health Technology
(0.0% 1d) (-6.6% 1m) (-34.5% 1y) (0.0% 2d) (-12.2% 3d) (-8.4% 7d) (258.4% volume)
Earnings Calendar:
http://www.ngmbio.com
Sec Filling | Patents | 186 employees
(US) NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for cardio-metabolic, liver, oncologic, and ophthalmic diseases. Its portfolio include aldafermin (NGM282), NGM313, NGM120, NGM217, NGM621, and NGM395. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
liver metabolic
add to watch list email alert is off
Price chart
% (High / Open) change chart
Press-releases
NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors
Published: 2022-05-12 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: 0.95%
H: 12.73%
C: 6.74%
ngm438 treatment for
NGM Bio to Participate in Upcoming Investor Conferences
Published: 2022-04-20 (Crawled : 21:00) - globenewswire.com
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: 0.58%
H: 1.02%
C: -5.27%
NGM Bio Announces Initiation of Phase 1/1b Clinical Trial of NGM831 for the Treatment of Patients with Advanced Solid Tumors
Published: 2022-03-31 (Crawled : 22:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: 0.51%
H: 0.64%
C: -2.62%
ngm831 treatment trial
NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022
Published: 2022-03-21 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: -1.12%
H: 2.37%
C: -4.04%
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-01 (Crawled : 23:00) - globenewswire.com
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: -0.35%
H: 13.31%
C: 12.2%
financial results report results
NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Published: 2022-02-07 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: 3.61%
H: 6.52%
C: 6.0%
ngm621 fast track designation treatment fda fast track macular designation
NGM Bio Announces Clinical Trial Collaboration with Merck Related to Ongoing Phase 1/2 Trial of NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination with Merck’s KEYTRUDA® (pembrolizumab)
Published: 2021-12-06 (Crawled : 15:30) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
ongoing trial phase 1 keytruda collaboration antibody
NGM Bio to Participate in Upcoming Investor Conferences
Published: 2021-11-09 (Crawled : 21:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: 0.82%
H: 0.48%
C: 0.29%
conference
NGM Bio Provides Business Highlights and Reports Third Quarter 2021 Financial Results
Published: 2021-11-04 (Crawled : 23:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: 0.8%
H: 0.2%
C: -0.1%
financial results results
NGM Bio Presents Preliminary Findings from Ongoing Phase 1a/1b Dose Escalation Study of NGM120 in Patients with Advanced Solid Tumors at the ESMO Virtual Congress 2021
Published: 2021-09-16 (Crawled : 14:00) - biospace.com/
NGM 4 | $12.92 -12.23% 0.0% |
|
Health Technology
|
| O: -2.5%
H: 1.16%
C: -4.64%
solid tumors ongoing phase 1 phase 1b
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistLast 48 Hours Insiders Buying
ALTG P 3227 | $9.29 -2.52% 0.0% |
|
Distribution Services
| 01:40
SKIL P 30000 | $3.61 -6.96% 2.22% |
|
Information
| 23:50
CAMP P 20000 | $4.65 -1.27% 0.86% |
|
Electronic Technology
| 16:00